A recent study published in JAMA Network Open reveals a troubling surge in ivermectin prescriptions—doubling overall and tripling in the US South—following actor Mel Gibson’s endorsement of the drug as a cancer treatment on The Joe Rogan Experience podcast on January 9, 2025. The UCLA-led observational study, utilizing de-identified data from over 68 million patients via the TriNetX network, highlights a 2.5-fold increase among cancer patients, particularly among men and white individuals. While ivermectin, an FDA-approved anti-parasitic, and fenbendazole, a veterinary drug, have shown anti-cancer potential in preclinical studies, no randomized controlled trials (RCTs) support their efficacy or safety for human cancer treatment. This gap between lab results and clinical evidence underscores a critical public health issue: the rapid spread of unverified health claims through celebrity influence and social media, viewed by tens of millions in this case.

Beyond the study’s findings, this event fits into a broader pattern of health misinformation amplified by high-profile figures, reminiscent of the ivermectin craze during the COVID-19 pandemic. In 2021, endorsements by personalities like Joe Rogan himself led to a similar spike in off-label use, prompting FDA warnings about toxicity risks, including severe neurological effects at high doses (as noted in a 2021 MMWR report). What the original coverage misses is the systemic failure to address why vulnerable populations—cancer patients facing high mortality and often desperate for alternatives—are particularly susceptible. The study notes regional and demographic disparities (e.g., higher uptake in the South), but does not explore cultural or socioeconomic drivers, such as distrust in medical institutions or limited access to oncology care, which prior research (e.g., 2019 Pew Research Center surveys on medical mistrust) suggests play a role.

Moreover, the original article overlooks the role of algorithmic amplification on platforms like X and YouTube, where clips of Gibson’s claims spread virally. A 2022 study in Nature Communications found that health misinformation spreads six times faster than factual content online, often because it exploits emotional triggers like hope or fear—precisely what a cancer ‘cure’ narrative does. This incident also raises questions about accountability: neither the study nor initial reporting examines whether podcast platforms or influencers bear responsibility for vetting claims before broadcast, a debate gaining traction post-COVID misinformation scandals.

Synthesizing additional sources, a 2023 RCT in The Lancet Oncology on ivermectin for other off-label uses found no significant benefit and flagged gastrointestinal side effects in 12% of 200 participants, reinforcing the lack of evidence for non-parasitic applications. Meanwhile, a 2021 CDC report on ivermectin overdoses during the COVID-19 surge documented a 5-fold increase in poison control calls, a potential parallel risk now with cancer patients self-medicating. No conflicts of interest were disclosed in the JAMA study, though its observational design and convenience sample limit generalizability—key weaknesses compared to RCTs.

The deeper issue is not just one podcast or drug, but a public health education crisis. Cancer patients delaying proven therapies (e.g., chemotherapy, with 5-year survival gains of 30-50% per NCI data) for untested drugs risk catastrophic outcomes. Health systems must counter this with proactive, culturally tailored outreach—think targeted social media campaigns or community health worker programs—rather than reactive statements. Without addressing root causes like medical mistrust and digital misinformation ecosystems, celebrity-driven health fads will continue to outpace science.